[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100556674":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":30,"locations":40,"responsibleParty":59,"collaborators":24,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":69,"sex":70,"minAge":71,"maxAge":24,"enrollmentInfo":72,"targetDuration":24,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":24,"overallStatus":43,"whyStopped":24,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Centre Hospitalier Universitaire de Nice","OTHER",[8,14],{"label":9,"type":6,"description":10,"interventionNames":11},"Covid-long (CL+)","Assessment of musculoskeletal disorders, cognitive and neurocognitive assessments, Behavioral assessment, Work Difficulty Scale, Digital testing, brain MRI, Biological Analysis",[12,13],"Procedure: Brain MRI","Biological: Specific blood samples",{"label":15,"type":6,"description":16,"interventionNames":17},"Acute Covid (CL-)","Brain MRI, Biological Analysis",[12,13],[19,25],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"PROCEDURE","Brain MRI","non injected brain MRI",[15,9],null,{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":24},"BIOLOGICAL","Specific blood samples","blood samples to find immunological and inflammatory markers",[15,9],[31,36],{"name":32,"role":33,"phone":34,"phoneExt":24,"email":35},"Michel CARLES, PhD","CONTACT","04 92 03 55 15","carles.m@chu-nice.fr",{"name":37,"role":33,"phone":38,"phoneExt":24,"email":39},"Irit TOUITOU","04 92 03 58 47","touitou.i@chu-nice.fr",[41],{"facility":42,"status":43,"city":44,"state":24,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"CHU de NICE","RECRUITING","Nice","06200","France","FR",{"type":49,"coordinates":50},"Point",[51,52],7.26608,43.70313,{"lat":52,"lon":51},[55,57],{"name":56,"role":33,"phone":38,"phoneExt":24,"email":39},"TOUITOU Irit",{"name":32,"role":58,"phone":24,"phoneExt":24,"email":24},"PRINCIPAL_INVESTIGATOR",{"type":60,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100556674","covid-19-long-immunit-imagerie-cliim-100556674",false,"NCT06528171","Covid-19 Long Immunité IMagerie (CLIIM)","Specific Markers of Covid-long Syndrome: Identifying the Mechanisms Involved With a View to Defining Diagnostic Criteria","CLIIM","FOR CL+ PATIENTS\n\nInclusion Criteria:\n\n* Case definition in line with WHO Delphi process\n\nExclusion Criteria:\n\n* History of chronic fatigue syndrome diagnosed before or after Covid.\n* History of progressive psychiatric pathology.\n* History of acute Covid requiring admission to intensive care and mechanical ventilation.\n* No social security affiliation.\n\nFOR CONTROL (CL-)\n\nInclusion Criteria:\n\n* History of acute COVID-19, mild, moderate or severe (episode at least 3 months at the time of inclusion).\n* Absence of persistent symptoms more than 3 months after first Covid symptoms (or mild not affecting daily activities).\n\nExclusion Criteria:\n\n* History of progressive psychiatric pathology.\n* History of acute Covid requiring admission to intensive care and mechanical ventilation.\n* No social security affiliation.\n* Pregnant or breast-feeding.",true,"ALL","18 Years",{"count":73,"type":74},200,"ESTIMATED","INTERVENTIONAL",[77],"NA","Covid-long pathology affects a large number of patients, and represents a major medical, economic and societal challenge. To date, we have no objective criterion for a definitive diagnosis, nor any predictive tool for monitoring the evolution of Covid-long. Based on recruitment from the infectious diseases department of Nice University Hospital, the investigator's team wants to conduct an innovative pathophysiological study to better define the disease and identify specific biomarkers that could subsequently be used as a diagnostic tool for Covid-long. 120 participants will be initially included for the model learning phase: 60 controls in the CL- cohort and 60 patients in the CL+ cohort. Then 80 patients (40 CL+ and 40 Cl-) will be enrolled for the model validation phase.",[80],"COVID Long-Haul","2026-06-18",{"date":83,"type":84},"2026-06-22","ACTUAL",{"date":86,"type":84},"2024-12-06",{"date":88,"type":74},"2028-06",{"name":5,"class":6},1]